Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Infectious diseases 14

Infectious Diseases

recent-pharma-happenings-for-pfizer-biontech-oncoimmune-recursion

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates

Pfizer, BioNTech report shows the immune response in animals to COVID-19 Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, each based on a different mRNA format. The companies are now exhibiting that the most advanced candidate, BNT162b2, performed well in trials in which mice and macaques were infected with the coronavirus after inoculation. The companies informed that the vaccine candidate produced neutralizing antibodies against SARS-CoV-2, the virus that causes COVID-19, macaques, and antigen-specific CD4+ and CD8+ T cells in both the nonhuman primates and mice. Those T cell responses indicate an anti-viral immun...

Explore More...

Dengvaxia study; Opdivo racks up; FDA issues plant; Teva’s Rimsa fraud; Mission bags Fox grant

Business Cocktail

Antibiotic Resistance: The Big Challenge of Healthcare Industry

Hepatitis C drugs re-energize global fight over patents

Vulvovaginal Candidiasis

Cytomegalovirus infection Market

Science Events of the Year

CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective

Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika

Merck’s Antibody for Clostridium Difficile

Biosimilar Market in India

Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV

dengvaxia

Dengvaxia: Boon for Dengue

Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement

FDA Approves STELARA; Novartis announces AMG 334; AbbVie’s HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction

FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly